基于机制研究的支气管哮喘靶向药物治疗进展  

Antibody drug for bronchial asthma based on mechanism researches

作　　者：杜小曼 佟训靓[2] DU Xiao-man;TONG Xun-liang(Department of Respiratory and Critical Care Medicine ,Beijing Hospital,National Geriatrics Center, Beijing 100730,China;Department of Geriatric Medicine,Beijing Hospital,National Geriatrics Center, Beijing 100730,China)

机构地区：[1]北京医院呼吸与危重症医学科,北京100730 [2]北京医院保健医疗部国家老年医学中心,北京100730

出　　处：《临床药物治疗杂志》2019年第1期31-35,共5页Clinical Medication Journal

基　　金：北京医院科技新星计划(BJ-2016-038

摘　　要：近年来,随着支气管哮喘发病机制相关信号通路研究的不断深入,基于其机制研发了一些新的靶向药物。这些药物正逐步进入临床研究阶段,部分药物已经通过临床试验,最终进入临床使用,给临床医师带来更多的精准治疗的选择。本文将从支气管哮喘的病理生理机制、不同信号通路的功能的角度,对靶向药物在支气管哮喘中的应用做一系统综述,以期加深对靶向药物作用机制的理解,并为临床工作中治疗方案的选择提供参考和依据。With the deep research on the mechanism of asthma,especially its related signal pathway,lots of new antibody drugs entered into clinical research stage,some of which had passed the clinical trials and finally come into the process of clinical usage.Here,we focus on the different signal pathways involved in pathophysiology process of asthma,the targets of the antibody drugs design,and the key points which could affect the clinical usage.This article has summarized the features of designed antibody drugs in order to help clinicians to understand the mechanism of the new drugs on markets and provid novel choice in clinical practice.

关 键 词：支气管哮喘 机制研究 靶向治疗 

分 类 号：R976[医药卫生—药品]